Literature DB >> 22819233

Citrulline and arginine utility in treating nitric oxide deficiency in mitochondrial disorders.

Ayman W El-Hattab1, Lisa T Emrick, William J Craigen, Fernando Scaglia.   

Abstract

Mitochondrial diseases arise as a result of dysfunction of the respiratory chain, leading to inadequate ATP production required to meet the energy needs of various organs. On the other hand, nitric oxide (NO) deficiency can occur in mitochondrial diseases and potentially play major roles in the pathogenesis of several complications including stroke-like episodes, myopathy, diabetes, and lactic acidosis. NO deficiency in mitochondrial disorders can result from multiple factors including decreased NO production due to endothelial dysfunction, NO sequestration by cytochrome c oxidase, NO shunting into reactive nitrogen species formation, and decreased availability of the NO precursors arginine and citrulline. Arginine and citrulline supplementation can result in increased NO production and hence potentially have therapeutic effects on NO deficiency-related manifestations of mitochondrial diseases. Citrulline is a more efficient NO donor than arginine as it results in a greater increase in de novo arginine synthesis, which plays a major role in driving NO production. This concept is supported by the observation that the three enzymes responsible for recycling citrulline to NO (argininosuccinate synthase and lyase, and nitric oxide synthase) function as a complex that can result in compartmentalizing NO synthesis and channeling citrulline efficiently to NO synthesis. Clinical research evaluating the effect of arginine and citrulline in mitochondrial diseases is limited to uncontrolled open label studies demonstrating that arginine administration to subjects with MELAS syndrome results in improvement in the clinical symptoms associated with stroke-like episodes and a decrease in the frequency and severity of these episodes. Therefore, controlled clinical studies of the effects of arginine or citrulline supplementation on different aspects of mitochondrial diseases are needed to explore the potential therapeutic effects of these NO donors.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22819233     DOI: 10.1016/j.ymgme.2012.06.018

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  36 in total

1.  Arginine and citrulline for the treatment of MELAS syndrome.

Authors:  Ayman W El-Hattab; Mohammed Almannai; Fernando Scaglia
Journal:  J Inborn Errors Metab Screen       Date:  2017-03-24

2.  Late onset MELAS with m.3243A > G mutation and its association with aneurysm formation.

Authors:  Kun Zhu; Shuang Li; Huan Chen; Yao Wang; Miao Yu; Hongyan Wang; Weijie Zhao; Yunpeng Cao
Journal:  Metab Brain Dis       Date:  2017-03-21       Impact factor: 3.584

3.  Mitochondrial Dysfunction: Metabolic Drivers of Pulmonary Hypertension.

Authors:  Hagir B Suliman; Eva Nozik-Grayck
Journal:  Antioxid Redox Signal       Date:  2019-02-25       Impact factor: 8.401

4.  8-year retrospective analysis of intravenous arginine therapy for acute metabolic strokes in pediatric mitochondrial disease.

Authors:  Rebecca D Ganetzky; Marni J Falk
Journal:  Mol Genet Metab       Date:  2018-02-02       Impact factor: 4.797

Review 5.  Mitochondrial biogenesis: regulation by endogenous gases during inflammation and organ stress.

Authors:  Hagir B Suliman; Claude A Piantadosi
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 6.  Therapeutic Approaches to Treat Mitochondrial Diseases: "One-Size-Fits-All" and "Precision Medicine" Strategies.

Authors:  Emanuela Bottani; Costanza Lamperti; Alessandro Prigione; Valeria Tiranti; Nicola Persico; Dario Brunetti
Journal:  Pharmaceutics       Date:  2020-11-11       Impact factor: 6.321

Review 7.  Therapies for mitochondrial diseases and current clinical trials.

Authors:  Ayman W El-Hattab; Ana Maria Zarante; Mohammed Almannai; Fernando Scaglia
Journal:  Mol Genet Metab       Date:  2017-09-18       Impact factor: 4.797

8.  Novel metabolic roles of L-arginine in body energy metabolism and possible clinical applications.

Authors:  K Hristina; T Langerholc; M Trapecar
Journal:  J Nutr Health Aging       Date:  2014       Impact factor: 4.075

9.  Nuclear recruitment of neuronal nitric-oxide synthase by α-syntrophin is crucial for the induction of mitochondrial biogenesis.

Authors:  Katia Aquilano; Sara Baldelli; Maria R Ciriolo
Journal:  J Biol Chem       Date:  2013-11-14       Impact factor: 5.157

10.  Mitochondrial dysfunction in brain cortex mitochondria of STZ-diabetic rats: effect of l-Arginine.

Authors:  M Del Carmen Ortiz; Silvia Lores-Arnaiz; M Florencia Albertoni Borghese; Sabrina Balonga; Agustina Lavagna; Ana Laura Filipuzzi; Daniela Cicerchia; Monica Majowicz; Juanita Bustamante
Journal:  Neurochem Res       Date:  2013-11-05       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.